Blar i Institutt for bioingeniørfag på forfatter "Hak, Sjoerd"

Viser treff 1-3 av 3

    • Cyclic Arginine–Glycine–Aspartate-Decorated Lipid Nanoparticle Targeting toward Inflammatory Lesions Involves Hitchhiking with Phagocytes 

      Sofias, Alexandros Marios; Bjørkøy, Geir; Ochando, Jordi; Sønstevold, Linda; Hegvik, Maria; Davies, Catharina de Lange; Haraldseth, Olav; Lammers, Twan; Mulder, Willem J. M.; Hak, Sjoerd (Peer reviewed; Journal article, 2021)
      Active-targeting nanomedicine formulations have an intricate in vivo behavior. Nanomedicines developed to target endothelial αvβ3-integrin are recently demonstrated to display extensive uptake by circulating phagocytes. ...

    • Discovery of a new marker to identify myeloid cells associated with metastatic breast tumours 

      Bokil, Ansooya Avinash; Børkja, Mathieu; Wolowczyk, Camilla Izabel; Lamsal, Apsana; Prestvik, Wenche S.; Nonstad, Unni; Pettersen, Kristine; Andersen, Sonja Benedikte; Bofin, Anna M.; Bjørkøy, Geir; Hak, Sjoerd; Giambelluca, Miriam Soledad (Peer reviewed; Journal article, 2023)
      Background: Myeloid cells play an essential role in cancer metastasis. The phenotypic diversity of these cells during cancer development has attracted great interest; however, their functional heterogeneity and plasticity ...

    • Tumor Targeting by αvβ3-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking 

      Sofias, Alexandros Marios; Toner, Yohana C.; Meerwaldt, Anu E.; van Leent, Mandy M. T.; Soultanidis, Georgios; Elschot, Mattijs; Gonai, Haruki; Grendstad, Kristin; Flobak, Åsmund; Neckmann, Ulrike; Wolowczyk, Camilla; Fisher, Elizabeth L.; Reiner, Thomas; Davies, Catharina de Lange; Bjørkøy, Geir; Teunissen, Abraham J. P.; Ochando, Jordi; Pérez-Medina, Carlos; Mulder, Willem J. M.; Hak, Sjoerd (Journal article; Peer reviewed, 2020)
      Although the first nanomedicine was clinically approved more than two decades ago, nanoparticles’ (NP) in vivo behavior is complex and the immune system’s role in their application remains elusive. At present, only ...